Meeting
2023 ASCO Annual Meeting
Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated biliary tract cancer.
Authors
Wen-Zhuo He
Sun Yat-sen University Cancer Center, Guangzhou, China
Wen-Zhuo He , Han-Bin Lin , Gui-Fang Guo , Liang-Ping Xia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4071)
DOI
10.1200/JCO.2023.41.16_suppl.4071
Abstract #
4071
Poster Bd #
392
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Galectin-9 as a regulator of immune interactions in the tumor microenvironment and novel therapeutic target in biliary tract cancer.
First Author: Emilie AK Warren
Poster
2022 ASCO Annual Meeting
Identification of super-exhausted T cells: A novel population predictive of response to immunotherapy.
First Author: Florent Peyraud
Poster
2020 Genitourinary Cancers Symposium
NIVOREN GETUG-AFU 26 translational study: Association of PD-1, AXL, and PBRM-1 with outcomes in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N).
First Author: Yann-Alexandre Vano
Poster
2019 Gastrointestinal Cancers Symposium
Activation of central/effector memory T cells in advanced gastric cancer patients treated with antiprogrammed death-1 antibody.
First Author: Hirofumi Ohmura